|
Synonyms: Ogsiveo® | PF-03084014 | PF3084014 | Z-3181
nirogacestat is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Nirogacestat (PF-3084014) is compound 14f in [2] where it is described as a centrally active γ-secretase inhibitor. It is a reversible, non-competitive, and orally bioactive agent. The compound prevents proteolytic cleavage of the Notch receptor and release of the oncogenic Notch intracellular domain fragment. This disrupts downstream pathway signalling via all 4 human Notch receptors and leads to cell cycle arrest and apoptosis in tumour cells [1,3,8,11,11-12]. Nirogacestat binds directly within the catalytic substrate-binding pocket of the presenilin 1 (PSEN1) γ secretase subunit.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| In a whole cell assay PF-3084014 inhibits γ-secretase activity with an IC50 of 1.2nM [2], measured as a reduction of Aβ formation. The compound also reduced Aβ in guinea pig brain. |